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Abstract: 
 
Mast cells (MC) are important immune sentinels found in most tissue and widely recognized for 
their role as mediators of Type I hypersensitivity. However, they also secrete anti-cancer 
mediators such as tumor necrosis factor alpha (TNF-α) and granulocyte-macrophage colony-
stimulating factor (GM-CSF). The purpose of this study was to investigate adipose tissue as a 
new source of MC in quantities that could be used to study MC biology focusing on their ability 
to bind to and kill breast cancer cells. We tested several cell culture media previously 
demonstrated to induce MC differentiation. We report here the generation of functional human 
MC from adipose tissue. The adipose-derived mast cells (ADMC) are phenotypically and 
functionally similar to connective tissue expressing tryptase, chymase, c-kit, and FcεRI and 
capable of degranulating after cross-linking of FcεRI. The ADMC, sensitized with anti-
HER2/neu IgE antibodies with human constant regions (trastuzumab IgE and/or C6MH3-B1 
IgE), bound to and released MC mediators when incubated with HER2/neu-positive human 
breast cancer cells (SK-BR-3 and BT-474). Importantly, the HER2/neu IgE-sensitized ADMC 
induced breast cancer cell (SK-BR-3) death through apoptosis. Breast cancer cell apoptosis was 
observed after the addition of cell-free supernatants containing mediators released from FcεRI-
challenged ADMC. Apoptosis was significantly reduced when TNF-α blocking antibodies were 
added to the media. Adipose tissue represents a source MC that could be used for multiple 
research purposes and potentially as a cell-mediated cancer immunotherapy through the 
expansion of autologous (or allogeneic) MC that can be targeted to tumors through IgE 
antibodies recognizing tumor specific antigens. 
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Mast cells (MC) are important immune sentinels found in most tissue and widely
recognized for their role as mediators of Type I hypersensitivity. However, they also
secrete anti-cancer mediators such as tumor necrosis factor alpha (TNF-α) and
granulocyte-macrophage colony-stimulating factor (GM-CSF). The purpose of this study
was to investigate adipose tissue as a new source of MC in quantities that could be
used to study MC biology focusing on their ability to bind to and kill breast cancer
cells. We tested several cell culture media previously demonstrated to induce MC
differentiation. We report here the generation of functional human MC from adipose
tissue. The adipose-derived mast cells (ADMC) are phenotypically and functionally similar
to connective tissue expressing tryptase, chymase, c-kit, and FcεRI and capable of
degranulating after cross-linking of FcεRI. The ADMC, sensitized with anti-HER2/neu
IgE antibodies with human constant regions (trastuzumab IgE and/or C6MH3-B1 IgE),
bound to and released MC mediators when incubated with HER2/neu-positive human
breast cancer cells (SK-BR-3 and BT-474). Importantly, the HER2/neu IgE-sensitized
ADMC induced breast cancer cell (SK-BR-3) death through apoptosis. Breast cancer cell
apoptosis was observed after the addition of cell-free supernatants containing mediators
released from FcεRI-challenged ADMC. Apoptosis was significantly reduced when TNF-α
blocking antibodies were added to the media. Adipose tissue represents a source MC
that could be used for multiple research purposes and potentially as a cell-mediated
cancer immunotherapy through the expansion of autologous (or allogeneic) MC that can
be targeted to tumors through IgE antibodies recognizing tumor specific antigens.
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INTRODUCTION
Mast cells (MC) are resident tissue immune cells that play
an important role in innate and acquired immunity, but are
most widely recognized in their role as regulators of Type
I hypersensitivity (1, 2). Differences in MC phenotypes and
functional responses between species have hampered progress
in understanding their role in several disease processes (2–
7). This incongruence has directed efforts toward obtaining
sources of human MC that can be used to evaluate the
role of these cells in basic mechanisms of disease without
confounding differences between rodent and human systems
(4, 5, 8). For example, MC can be obtained by culturing
progenitor cells from cord blood, venous blood, fetal liver,
bone marrow, and skin (8–12). However, variations in culture
conditions and the resulting MC that are phenotypically and
functionally immature still result in limitations that have
hindered MC research. Thus, new sources of human MC are
consistently needed.
One disease in which the role of MC has been investigated
is cancer (13–15). It is controversial as to their role in this
disease in light of contradictory findings between model systems
and species and that studies in humans are solely correlative
(i.e., an increase in MC numbers equates to poor prognosis
(13, 16–18). Human MC contain several pro-inflammatory
mediators, but are unique in their ability to pre-store and release
potentially beneficial anti-cancer mediators. For example, human
MC have pre-stored and releasable (through FcεRI engagement)
tumor necrosis factor alpha (TNF-α) within their granules
(2). Furthermore, human MC release granulocyte-macrophage
colony-stimulating factor (GM-CSF) upon FcεRI stimulation
(19, 20). Both TNF-α and GM-CSF have been used as anti-
cancer agents (21, 22). Correlative studies in humans cannot
address if the MC are affecting tumor growth; whether their
presence enhances, inhibits, or are non-participating bystanders.
Thus, developing ways to use MC to target tumors will aid
researchers in determining the functional role of these cells in
various tumors. In addition, harnessing anti-tumor agents from
MC as a potential “Trojan Horse” may represent a new form of
cancer cellular immunotherapy.
Human adipose tissue is a heterogeneous tissue containing the
stroma-vascular (SVF) fraction that includes a large population
of immune progenitor cells (23) and is a reservoir of functional
MC progenitors in mice (24). We report here that large numbers
of functional human MC can be expanded from human adipose
tissue. The adipose-derived MC (ADMC) are phenotypically
and functionally similar to connective tissue MC obtained from
skin as assessed through MC-specific markers and IgE- and
non-IgE-dependentmediator release assays. Importantly, ADMC
sensitized with anti-HER2/neu IgE antibodies (Abs) are able to
induce cell death in breast cancer cells overexpressing HER2/neu.
Adipose tissue now provides researchers a new source of human
Abbreviations: MC, mast cells; Abs, antibodies; ADMC, adipose-derived mast
cells; TNF-α, tumor necrosis factor alpha; GM-CSF, granulocyte-macrophage
colony-stimulating factor; SCF, stem cell factor; PI, propidium iodide; APC,
antigen presenting cells; Tregs, Regulatory T cells; NS, non-specific.
MC that could be used for multiple research purposes and as a
potential new strategy for cell-mediated cancer immunotherapy.
MATERIALS AND METHODS
Consent Statement
Tissue procurement and IRB approval including patient consent
were obtained from the Cooperative Human Tissue Network.
Adipose Tissue Digestion
Skin and adipose tissue was obtained from patients undergoing
cosmetic surgery. Adipose tissue was incubated with Hanks’
balanced salt solution (HBSS), 1% fetal bovine serum, 0.04%
sodium bicarbonate, 1% HEPES, 0.5% amphotericin B, 1%
streptomycin/penicillin and 0.1% collagenase type 1A. Cells were
placed into a 37◦C orbital shaker for 1 h with constant agitation
at 4 × g. The cell slurry was centrifuged at 360 × g for 15min
and adipocytes washed, suspended in medium (DMEM with 4.5
g/L glucose, 10% fetal bovine serum, 1% streptomycin/penicillin,
1% L-glutamine and 1% HEPES), and cultured for up to 7
days or until the stem cells were confluent before testing of
MC-differentiating media below.
Mast Cell Differentiation
Different cell culture media were tested for their ability to
induce MC differentiation of the adipose cells using X-VIVO
15 or AIM-V (Lonza, Switzerland), plus 80 ng/ml SCF (Stemcell
Technologies, Vancouver, BC) with or without non-specific (NS)
psIgE (human myeloma IgE; a gift from Dr. Andrew Saxon,
UCLA; 0.1µg/ml). Conditioned MC media was produced using
media used to culture primary human skin MC as described (12,
25). Briefly, skin MC cultures (>5 weeks) containing 80 ng/ml
SCF in X-VIVO 15 were pelleted by centrifugation, supernatants
removed, filtered through a 22µm filter (Sigma-Aldrich, St.
Louis, MO) to remove any cells, and added directly to the adipose
stem cells (∼15ml per 75/mm2 flask). Approximately every seven
to 10 days, viability was assessed by trypan blue exclusion and half
of the media was collected and replaced with fresh media. Initial
monitoring ofMCdifferentiation was determined using toluidine
blue staining of cytospins followed by further characterization as
described below.
Flow Cytometry
Flow cytometry was performed using a FACS Arial III (Becton
Dickenson, Franklin Lakes, NJ). Briefly, mouse anti-human Abs
to FcεRI, c-kit, FcγRI, FcγRII, FcγRIII (Santa Cruz, Dallas,
TX), or mouse IgG isotype control MOPC (Sigma-Aldrich) were
added for at least 1 h on ice, washed, and F(ab′)2-FITC-goat anti-
mouse Abs (BD Biosciences, San Jose, CA) added for detection
(26). All experiments were performed at least three times.
Cytochemistry and Immunofluorescence
Immunochemistry was performed with mouse anti-human
Abs to tryptase and chymase or NS mouse IgG isotype
(negative) control as described (27, 28) but using Cy3-conjugated
anti-mouse secondary Abs. For detection of ADMC-induced
apoptosis of human breast cancer SK-BR-3 cells (ATCC,
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Manassas, VA), cell cytospins were incubated with 1µg/ml Alexa
FluorTM 488 dye (ThermoFisher Scientific, Walnut, CA) labeled
mouse anti-human tryptase (1µg/ml; for ADMC detection;
green) along with Alexa FluorTM 647 labeled mouse anti-human
Ab to the active form of caspase 3 (1µg/ml; for SK-BR-3
detection; red) or Alexa FluorTM 647 labeled isotype control
for the caspase 3 Ab. To quantify the percentage of caspase 3
positive cells observed on the cytospins a total of 200 cells were
counted on each slide and the number of SK-BR-3 cells positive
for caspase activation was compared to the number of those not
stained for caspase 3 that were not MC.
Gene Expression
RNA was extracted from ADMC using the Qiagen RNeasy Plus
Mini kit (Qiagen, Germany). Reverse Transcriptase PCR (RT-
PCR) was performed using theQiagenOneStep RT-PCR kit using
primers previously described to amplify short fragments of the β-
actin, tryptase, chymase, c-KIT, and FcεR1α RNA (29). Cycling
conditions were: 50◦C for 30min, 95◦C for 15min, followed by
35 cycles of 94◦C for 45 s, 53–63◦C for 45 s (according to primer
Tm), 72
◦C for 1min and a final 10min extension at 72◦C.
Anti-HER2/neu IgE Abs and Extracellular
Domain of HER2/neu (ECDHER2)
The fully human anti-human HER2/neu IgE/kappa containing
the variable regions of the human scFv C6MH3-B1 has been
previously described (30). In addition, we also developed
an anti-human HER2/neu IgE/kappa containing the variable
regions of the humanized Ab trastuzumab (Herceptin R©) by
subcloning the variable regions of trastuzumab previously
used in Ab-cytokine fusion proteins (31, 32) into the human
epsilon/kappa expression vectors use to the develop the C6MH3-
B1 IgE. The trastuzumab IgE and C6MH3-B1 IgE bind
different epitopes of human HER2/neu. They are expressed in
murine myeloma cells and the transfectomas grown in roller
bottles for Ab production as described (30). The IgE Abs are
purified from cell culture supernatants on an immunoaffinity
column prepared with omalizumab (Xolair R©) (Genentech, Inc.
San Fransisco, CA, USA) (30). The extracellular domain of
HER2/neu (ECDHER2) was produced as described previously
(31). All proteins were quantified using the BCA Protein Assay
(ThermoFisher Scientific).
Degranulation and Cytokine Production
From ADMC
To determine ADMC functional responses mediated through
FcεRI, ADMC were incubated with 1µg/ml of anti-FcεRI
Abs or with 1µg/ml anti-NP IgE for 1 h followed by NP-
BSA. To determine ADMC functional responses mediated
by non-IgE pathways, ADMC were incubated with 40µg/ml
Poly-L-Lysine (Sigma-Aldrich) or 10µM A23187 (Sigma-
Aldrich). Post-incubation, activation was performed for
30min (to measure degranulation) or overnight (for cytokine
analysis) and β-hexosaminidase release and TNF-α and GM-
CSF production were measured as described (33–35). All
experiments were performed in duplicate from four separate
donors and significant differences (p<0.05) determined using the
Student t-test.
HER2/neu IgE-Mediated Binding of ADMC
to Breast Cancer Cells
To assess the ability of anti-HER2/neu IgE sensitized ADMC
to bind to HER2/neu expressing SK-BR-3 breast cancer cells,
confocal imaging was used on differentially labeled, live cells.
The ADMC (1.5 × 105) were sensitized with 1µg/ml of anti-
HER2/neu IgE Abs or NS psIgE followed by the addition of
MitoTrackerTM Green (500 nM; ThermoFisher Scientific). The
ADMC were washed once in warm X-VIVO 15 and added to
the adherent, human HER2/neu-positive SK-BR-3 cells that were
pre-stained with MitoTrackerTM Red (500 nM; ThermoFisher
Scientific) in a live cell incubator affixed to a confocal microscope
and images acquired over 6 h.
Breast Cancer Cell-Induced Mediator
Release From ADMC
ADMC were sensitized with or without 1µg/ml of anti-
HER2/neu IgE or NS psIgE as above and added to human
breast cancer cells expressing high levels of HER2/neu SK-
BR-3 or BT-474 (a gift from Dr. Hui-Wen Lo, Wake
Forest University) cells for 1 h in 24 well plates. The ratio
of MC to breast cancer cells varied from 1:10 to 10:1
ADMC to breast cancer cells and mediators assessed in the
supernatants. In some experiments anti-HER2/neu IgE sensitized
ADMC challenged with ECDHER2 or heat-inactivated serum
from patients with HER/neu positive breast cancer (Cureline,
Brisbane, CA; Table 1).
HER2/neu IgE-Mediated Killing of Breast
Cancer Cells by ADMC and Supernatants
From Activated ADMC
Three different methods were used to assess the ability of
anti-HER2/neu IgE sensitized ADMC to induce cell death of
HER2/neu expressing breast cancer cells. First, ADMC (1.5
× 105) were sensitized with 1µg/ml of anti-HER2/neu IgE
TABLE 1 | HER2/neu positive breast cancer patient serum.
Serum Diagnosis Age Pathological
diagnosis
Grade TNM
staging (T)
TNM
staging (N)
TNM
staging (M)
Stage HER2/neu
status
Treatment
history
P1 Breast
carcinoma
64 Infiltrative ductal
carcinoma
G3 T2 N1 M0 IIB 2+ None
(treatment-naive)
P2 Breast
carcinoma
35 Infiltrative introductal
carcinoma
G1 T1 N0 M0 IA 3+ None
(treatment-naive)
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TABLE 2 | Media used for MC differentiation.
Media Media additions MC numbers
80 ng/ml 0.1 µg/ml
AIM-V SCF +
SCF IgE +
X-VIVO 15 SCF +
SCF IgE ++
Conditioned media None added +++
or psIgE for 2 h. Breast cancer cells (5 × 104) on coverslips
were labeled with 2µM MitoTrackerTM Green (ThermoFisher
Scientific) for 1 h. The washed ADMC were labeled with
CellTrackerTM Deep Red (which stains the cells reddish/purple
under confocal; 2µM) for 1 h, washed, and added to SK-BR-
3 in medium containing 25µg/ml of propidium iodide (PI;
which stains the cells red) used to detect dead cells (36) and
PI intensity measured over time. Second, SK-BR-3 were plated
and incubated with CelleventTM Caspase 3/7 Green (to detect
activated caspase-3/7 in apoptotic cells; ThermoFisher Scientific)
for 1 h according to the manufacturers protocol. ADMC, treated
with MitoTrackerTM Red (1µg/ml), were added to the washed
SK-BR-3 cells and incubated for up to 4 days. Third, cytospins
of cells from separate experiments were made and used for
immunofluorescence detection of apoptosis. Briefly, cytospins
were fixed in methanol and incubated with Alexa FluorTM
488 dye (ThermoFisher Scientific) labeled mouse anti-human
tryptase (1µg/ml; for ADMC detection; green, for co-cultures)
along with Alexa FluorTM 647 labeled mouse anti-human active
caspase 3 (BD Biosciences, 1µg/ml; for SK-BR-3 detection; red)
Alexa FluorTM 647 labeled isotype Abs were used as a control for
the caspase 3 Ab.
In separate experiments, cell free supernatants from optimally
activated ADMC (1.3 × 106) by an anti-FcεRI Ab (1µg/ml for
24 h; 60–70% release) were directly added to MitoTracker
TM
Green-labeled SK-BR-3 cells (5 × 104). In some experiments, an
anti-human TNF-α Ab (5µg/ml) was added to the supernatants
to block TNF-α activity. Cell death was monitored over time
through the quantification caspase 3/7-positive cells (>200)
counted at the end of each experiment to obtain percentages. All
confocal/live cell experiments were performed on three separate
ADMC donors and significance (p < 0.05) tested using the
Student’s t-test.
RESULTS
Phenotypic Characterization of ADMC
Several culture conditions were tested for their ability to induce
MC differentiation (35, 37). The conditioned media from skin-
derived human MC cultures was found to be optimal for ADMC
differentiation (Table 2). In conditioned medium, ADMC were
observed to emerge from large clumps of cells or tissue as shown
in Figure 1A. After 3–4 weeks of culture, mature MC (>90%
viable) were observed as demonstrated by the classical spherical,
highly granulated morphology (Figure 1B) characteristic of skin-
derived MC (Figure 1C). In addition, the ADMC were positive
for messenger RNA to the two major MC proteases, tryptase,
and chymase (Figure 1D). Furthermore, the ADMC expressed
surface markers for tissue MC including FcεRI and the receptor
for SCF, c-kit (Figure 1E). As previously reported with skin
MC (26), ADMC express FcγRII and not FcγRI or FcγRIII
(Figure 1F). As seen in Figure 1G both tryptase and chymase
protein was detected using immunohistochemistry. Thus,
adipose tissue has MC progenitors that can be differentiated
into MC that are phenotypically similar to human connective
tissue (MCTC) (38) based on these characteristics. Representative
numbers of ADMC obtained from surgical specimens are
shown in Table 3.
Functional Characterization of ADMC
The functional response of ADMCwas compared to skin-derived
MC. As seen in Figure 2, ADMC degranulated (Figure 2A)
and produced cytokines (Figure 2B) in response to FcεRI
engagement. Cytokine release by ADMC and skin MC was
similar in response to FcεRI-dependent stimuli averaging
2,850 and 2,600 pg/ml of GM-CSF in skin MC and ADMC,
respectively. A similar degranulatory response with ADMC was
observed using non-FcεRI-dependent stimuli Poly-L-Lysine and
A23187 (Supplemental Figure 1). Taken together, the ADMC are
functionally similar to skin-derived MC in response to FcεRI-
dependent and FcεRI-independent stimuli.
Anti-HER2/neu IgE Mediates ADMC
Binding to SK-BR-3 Breast Cancer Cells
The ability of ADMC sensitized with the anti-HER2/neu IgE
to bind HER2/neu–positive SK-BR-3 breast cancer cells was
investigated. As seen in Figure 3A, the ADMC sensitized with
the anti-HER2/neu IgE (green) bound to HER2/neu-positive SK-
BR-3 breast cancer cells (red) as demonstrated in the time lapse
pictures and video (Supplemental Video 1). However, ADMC
sensitized with a NS IgE did not target or bind to the SK-
BR-3 cells (Figure 3B). These results demonstrate that the anti-
HER2/neu-IgE mediates the interaction between ADMC and
HER2/neu-positive breast cancer cells.
Anti-HER2/neu IgE-Sensitized ADMC
Become Activated Through FcεRI Upon
HER2/neu—Positive Breast Cancer Cell
Binding
ADMC must release their mediators upon FcεRI challenge
at the site of the tumor to be effective anti-tumor agents.
Thus, the ability of ADMC sensitized with the anti-HER2/neu
IgE to degranulate in the presence of breast cancer cells was
investigated. ADMC were sensitized with one of two anti-
HER2/neu IgE Abs recognizing different epitopes (trastuzumab
IgE or C6MH3-B1 IgE). Varying ADMC cell numbers were
incubated with SK-BR-3 breast cancer cells and mediator release
assessed in the medium. As seen in Figure 4, ADMC sensitized
with anti-HER2/neu IgE induced significant (p<0.05) mediator
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FIGURE 1 | Phenotypic characterization of ADMC. (A) Light microscopy of ADMC. ADMC cultures demonstrating large cell/tissue clumps from which the MC
differentiate (20 × magnification). Cytospins of adipose-derived (B) or skin MC (C) were stained with toluidine blue. (D) Gene expression was measured using RT-PCR
on total RNA. β-actin and 18S ribosomal subunit primers were controls (Ladder: bp). (E) Surface expression of MC-specific markers by flow cytometry. ADMC were
incubated with mouse anti-c-Kit/CD117 (dashed line), FcεRIα chain (solid line), or isotype control mouse IgG (gray) for 2 h on ice, washed, and F(ab′)2-FITC-goat
anti-mouse added for 1 h. (F) Fcγ receptor expression on ADMC. ADMC were incubated with mouse anti human FcγRI (dotted), FcγRII (solid line), FcγRIII (dashed), or
isotype control mouse IgG (gray) for 2 h on ice, washed, and FITC-labeled anti-mouse F(ab′)2 added for 1 h. (G) Immunohistochemistry of ADMC with MC-specific
markers. Anti-tryptase, anti-chymase, or NS IgG Ab were incubated overnight on cytospin cells, washed and incubated with Cy3-secondary Abs and Hoechst dye
(blue nuclei) and visualized using confocal microscopy. Figures are representative of cells derived from three different human subjects.
release through FcεRI when co-incubated with the HER2/neu-
positive SK-BR-3 breast cancer cells. The ADMC degranulated
to release pre-stored mediators (Figure 4A), as well as newly
formed mediators TNF-α and GM-CSF (Figure 4B). Another
HER2/neu-positive breast cancer cell line, BT-474, also induced
degranulation and cytokine production optimally at a ratio of
1:2 (degranulation) and 1:0.5 (cytokine release) ADMC:BT-474
(Supplemental Figure 2).
The above results suggest the possibility of using ADMC
armed with IgE Abs can trigger degranulation in the presence of
HER2/neu expressing cancer cells and thus, the potential of using
this strategy for cancer therapy via the release of MC mediators.
However, a potential concern of the systemic administration of
ADMC sensitized with an anti-HER2/neu IgE is the possible
induction of a systemic anaphylactic reaction as patients with
HER2/neu breast cancer can have elevated levels of circulating
ECDHER2 in the blood (39, 40). The IgE Abs are not expected to
induce FcεRI cross-linking when complexed with soluble antigen
(ECDHER2), given the mono-epitopic nature of this interaction
and the fact that ECDHER2 does not form homodimers in
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solution (41, 42). To address this concern, the ability of ECDHER2
to induce FcεRI-mediator release was examined. As described
previously (30), ECDHER2 in the presence of the anti-HER2/neu
IgE Abs did not induce degranulation, while anti-FcεRI Abs
induced release (Figure 4C). Furthermore, serum from two
separate HER2/neu positive breast cancer patients did not induce
ADMC degranulation (Figure 4D). These results suggest that the
anti-HER2/neu IgE-sensitized ADMC will not induce a systemic
anaphylactic response in vivo and will only release mediators
upon encountering HER2/neu on breast cancer cells.
IgE Sensitized ADMC Induce SK-BR-3 Cell
Death
The ability of ADMC to induce breast cancer cell death was
investigated. ADMC sensitized with the anti-HER2/neu IgE were
added to SK-BR-3 cells in medium containing PI to discriminate
dead cells from live cells (36). As seen in Figure 5A, binding of
anti-HER2/neu–sensitized (trastuzumab IgE) ADMC to SK-BR-
3 cells induced significant cell death of the breast cancer cells as
assessed by the uptake and visualization (red) of the PI in the
SK-BR-3 cells but not the ADMC. Quantification of the PI signal
in Figure 5B demonstrated significant breast cancer cell killing
after 4 days (p= 0.0003). Sensitization of the ADMCwith NS IgE
did not result in significant SK-BR-3 cell death. Similarly, anti-
HER2/neu IgE C6MH3-B1 sensitized ADMC induced significant
(p = 0.032) SK-BR-3 cell death (data not shown). In addition,
ADMC added to the SK-BR-3 over 4 days revealed significant
(p = 0.003) breast cancer cell death, but not ADMC death (anti-
tryptase labeled), as indicated by immunostaining of the SK-
BR-3 with an Ab specific for the apoptotic enzyme caspase 3
(Figures 5C,D). Lastly, a significant (p = 0.0004) increase in
caspase 3/7-positive breast cancer cells was confirmed at day
4 when anti-HER2/neu–sensitized ADMC were co-incubated
(Figures 5E,F). The tumor cell specificity of the responses was
verified as the NS isotype control IgE did not affect breast
cancer cell viability. These experiments indicate ADMC binding
to SK-BR-3 results in ADMC activation through FcεRI capable of
inducing significant SK-BR-3 cell death.
Mediators Released From ADMC Through
FcεRI Induce SK-BR-3 Cell Death
As shown above, ADMC produce mediators that induce
significant breast cancer cell death upon FcεRI cross-linking
using a tumor-targed IgE. The ability of the mediators obtained
from FcεRI-activated ADMC alone to induce SK-BR-3 cell death
was then examined. As seen in Figures 6A,B, medium alone (not
containing ADMC) from optimally activated ADMC incubated
with SK-BR-3 cells induced significant (p = 0.009) SK-BR-
3 cell death when incubated for 4 days. Further, when the
media from optimally activated FcεRI ADMC were added to
the SK-BR-3, there was a significant (p = 0.01) increase of
apoptotic cells as evidenced by the increase in active caspase 3
(Figures 6C,D) indicating cell death of the breast cancer cells
as in Figure 5. A significant (p = 0.0002) increase in activated
caspase 3/7-positive breast cancer cells was confirmed at day
4 when SK-BR-3 cells were incubated with supernatants from
TABLE 3 | Representative MC numbers from skin vs. liposuction tissue using
conditioned medium.
Adipose source Starting
grams or ml
MC numbers at 8
weeks
Cells per
gram/ml
Skin resection; BF 50 g 9.9 × 106 2.0 × 105
Skin resection; BF 27 g 8.6 × 106 3.2 × 105
Skin resection; WF 23g 7.9 × 106 3.4 × 105
Skin resection; WF 32g 2.4 × 107 7.5 × 105
Skin resection; WF 38g 8.9 × 107 7.6 × 105
Average/g 4.8 × 105
Lipo; WF 150ml 4.1 × 107 2.7 × 105
Lipo; WF 500ml 3.2 × 108 6.4 × 105
Lipo; WF 750ml 5.6 × 108 7.5 × 105
Lipo; WF 200ml 7.1 × 107 3.6 × 105
Average/ml 5.1 × 105
BF, Black female; WF, White female.
ADMC activated through FcεRI (Figures 6E,F). Blocking TNF-α
activity significantly prevented SK-BR-3 cell death (Figure 6G).
DISCUSSION
Here we report that functional MC can be differentiated
from adipose tissue obtained from human subjects undergoing
cosmetic surgery procedures. This research discovery is notable
as there is an ever-present need for new sources of humanMC for
research, given the differences between human and rodent MC
phenotypes and functional responses (5–7). This incongruence
has led to confusion and inconsistent findings in the field of
MC biology and allergic mechanisms (8, 43, 44), especially in
Fc receptor expression and function (26). While a plethora of
human “mast cell” lines exist, each is wrought with phenotypic
and functional anomalies compared to primary human MC (8).
Primary human MC can be obtained from cord blood (45,
46), bone marrow (45), fetal liver (47), peripheral blood (48),
and human tissue (e.g., skin) (11). For autologous applications,
MC can be obtained from CD34+ hematopoietic progenitor
cells in the blood (49), but not in sufficient numbers for most
applications. For example, the total MC number generated from
1.0 × 108 lymphocytapheresis or peripheral blood mononuclear
cells averaged 2.5 × 106 and 2.4 × 106, respectively (50).
Large numbers of enriched CD34+ cells can also be obtained
commercially to increase the quantities of subsequent MC
following GM-CSF injection, apheresis, and subsequent positive
selection with magnetic beads has been described (48). However,
given the various protocols for differentiation the MC obtained
from these methods are not fully mature and functional. In
this report, approximately 5.1 × 105 ADMC were obtained per
ml of liposuction compared to 4.8 × 105 MC per gram of
skin. Thus, ADMC can be utilized as a relatively rapid, more
cost effective, and efficient method for studying MC biology
and function. Current efforts are focused on identifying the
molecule(s) in the conditioned media that are responsible for the
ADMC differentiation and maturation.
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FIGURE 2 | ADMC functional response. Human skin MC (black box) or ADMC (gray box; 106) were challenged with or without (spontaneous release) 1µg/ml
anti-FcεRI Abs or anti-NP IgE + antigen (IgE-Ag) and degranulation (A) or GM-CSF production (B) assessed in the supernatants. Error bars represent ± SD.
*p < 0.05 comparing skin MC vs. ADMC release. Figure is representative of cells derived from two different donors.
FIGURE 3 | Time lapse, confocal microscopy of ADMC binding to breast cancer cells. ADMC (105-106) were sensitized with 1µg/ml of trastuzumab IgE (A, 20X) or
NS IgE (B, 40X) followed by MitoTrackerTM Green. The MitoTrackerTM Green-loaded ADMC were added to adherent SK-BR-3 (105-106) that had been pre-stained
with MitoTrackerTM Red and time lapse video taken over 6 h. The white circular boundaries and arrows represent starting point and tracking of ADMC (green) at time 0
to SK-BR-3 (red) binding over the 6 h. 20X magnification was used to capture the cellular tracking (start and stop) that can be observed in accompanying video.
The role of MC in cancer is controversial as to whether
they are beneficial, harmful, or innocuous and is dependent on
the tumor type and location within the tumor in humans and
animal models (16, 18, 51–53). Animal models, mostly MC-
deficient mice, have suggested that MC and their mediators play
a pro-tumorigenic role (52). Yet, MC-deficient mouse models
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FIGURE 4 | Breast cancer cell-induced ADMC mediator release. ADMC were sensitized with 1µg/ml anti-HER/neu IgE (clone C6MH3-B1 IgE or trastuzumab IgE),
washed, and incubated with SK-BR-3 cells and degranulation (A) or cytokine release (B) assessed. Data are from a single experiment representative of experiments
performed on cells derived from four separate donors. Error bars represent ± SD. *p < 0.05 Compared with non-IgE (spontaneous) release. All values in (B) are
significant compared to spontaneous release. (C) ECDHER2 does not induce ADMC mediator release. ADMC were sensitized with 1µg/ml anti-HER/neu IgE as in (A),
washed, and incubated with ECDHER2 and mediator release assessed. As a control, optimal concentrations of 1µg/ml anti-FcεRI Ab were tested in parallel. Each
condition was tested in triplicate and is representative from two separate ADMC donors. Error bars represent ±SD. (D) Sera from HER2/neu positive breast cancer
patients does not induce ADMC degranulation. Heat inactivated sera from two separate HER2/neu positive breast cancer patients (P1 and P2; see Table 1) or normal
control serum (Ctrl) was used to challenge anti-HER/neu IgE (C6MH3-B1 IgE or trastuzumab IgE) sensitized ADMC and β-hexosaminidase release measured as
described. Background levels of β-hexosaminidase naturally found in the sera was subtracted from values. Experiment is representative of two separate ADMC
preparations each done in duplicate. Error bars represent ± SD.
have paradoxically indicated that in certain tumors, and even
in the same models, MC appear to play a protective role (52,
54). These contradictory results might reflect differences in the
stage, incongruences between animal models (i.e., MC knockout
through kit mutation vs. Cre mutation) and/or rodent MC
lines vs. human MC, grade, and subtypes of tumor; as well as
the different methods to identify MC. While in certain human
cancers the presence of MC is associated with poor prognosis,
in other malignancies, such as breast and colorectal cancer, the
presence of MC has been associated with a favorable clinical
prognosis depending on their location (55–58). Currently,
multiple questions remain as to the nature of the role of MC in
cancer pathogenesis.
Human MC are unique in that they have pre-stored TNF-
α stores within their granules (59, 60). Furthermore, human
MC release copious amounts (2,500–4,000 pg/ml from 105
cells) of GM-CSF upon FcεRI stimulation (19, 20). Indeed,
the above blocking experiments suggest TNF-α activity is
the major component in FcεRI-activated ADMC supernatants
that induces SK-BR-3 apoptosis (Figure 6G). TNF-α is an
anti-cancer agent shown to suppress tumor cell proliferation,
induce tumor regression, and used as an adjuvant that
enhances the anti-cancer effect of chemotherapeutic agents
(61–63). GM-CSF is also being investigated as an anti-
breast cancer therapeutic, including its use in combination
strategies with other immunotherapies (21, 64–67). There are
over 50 clinical trials completed or underway examining the
beneficial clinical effects of GM-CSF (www.clinicaltrials.gov). In
addition to GM-CSF and TNF-α, MC also store and release
several other potential anti-tumor mediators including reactive
oxygen species (ROS), prostaglandin D2 (PGD2), interleukin-
9 (IL-9), and heparin (2, 13). In one study cord blood-
derived MC and eosinophils, sensitized with an anti-CD20
IgE, were shown to kill CD20-positive cancer cells (68). Thus,
it may be possible that even in cases where MC may act
favoring the tumors in certain cases through a controlled
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FIGURE 5 | ADMC killing of human breast cancer cells measured as evidence by the uptake of PI. (A) CellTrackerTM-red labeled ADMC (7.5 × 104; shown here as
purple cells) were sensitized with 1µg/ml anti-HER2/neu IgE (clone trastuzumab), washed, and incubated with MitoTrackerTM-green-stained SK-BR-3 (105) in culture
medium containing PI and images taken before (A; left) and after (A; right) 96 h. The call out box shows a representative ADMC being activated through loss of
granularity over time. (Mag 20x). (B) Quantification of overall PI fluorescence before and after incubation. The percent of PI-positive cells was counted in culture. The
*p = 0.0003 SK-BR-3 cell death at day 4 compared to day 0 when ADMC where sensitized with anti-HER2/neu IgE. No cell death was observed with the NS IgE.
(C) ADMC-induced breast cancer cell apoptosis. Anti-HER2/neu IgE-sensitized ADMC (7.5 × 104) were incubated with SK-BR-3 (1 × 105) for 72 h, cytospins made,
fixed, and incubated with Alexa FluorTM 488 labeled, mouse anti-human tryptase (left; green) along with Alexa FluorTM 647 labeled, mouse anti-human caspase 3
(red) or Alexa FluorTM 647 labeled, isotype control IgG for caspase 3 Ab (right). (D) Quantification of overall Alexa FluorTM 647 fluorescence before and after
incubation. *p = 0.002 SK-BR-3 apoptosis comparing psIgE and anti-HER2/neu IgE-sensitized cells at day 4 from three experiments. (E) ADMC killing of human
breast cancer cells measured by caspase 3/7 activation MitotrackerTM-red labeled ADMC (7.5 × 104; shown here as red cells) were sensitized with 1µg/ml
anti-HER2/neu IgE (clone trastuzumab), washed, and incubated with caspase 3/7 green-labeled SK-BR-3 (105 and images taken before (A, left) and after (A; right)
96 h. (F) Quantification of overall caspase 3/7 fluorescence before and after incubation. The percent of caspase 3/7-positive cells was counted in culture. *p = 0.004
SK-BR-3 cell death at day 4 compared to day 0 when ADMC where sensitized with anti-HER2/neu IgE. No SK-BR-3 cell death was observed with the NS IgE.
release of certain agents, they may have anti-tumor activity
upon an IgE-mediated strong and immediate release of their
granular content. Given that these MC mediators may have
unwanted side effects, further in vivo studies are needed to
address this topic.
There are 21 FDA approved Abs on the market to treat
various cancers (69). While all are of the human IgG class, IgE
has several potential advantages over Abs of the IgG class, such
as the IgE-FcεRI high affinity interaction, which allows a more
effective arming of effector cells without losing surface-bound
Abs (30, 70, 71) and the low serum levels of IgE that result in
less competition for FcR occupancy (70–72). The first clinical
trial (www.clinicaltrials.gov; clinical trial number NCT02546921)
is currently underway in patients with advanced solid tumors
to examine the safety of a mouse/human chimeric IgE Ab
(MOv18 IgE), specific for the tumor-associated antigen folate
receptor-α, which has exhibited superior anti-tumor efficacy for
IgE compared with IgG1 in animal models (73, 74).
Three separate experimental approaches were used above
to demonstrate ADMC, and mediators from FcεRI-challenged
ADMC, have anti-tumor activity and suggests the possibility of
using autologous (or allogeneic) MC in cancer immunotherapy.
There are several advantages for this potential technology.
First, mature, functional, autologous or allogeneic MC can be
obtained in quantities necessary for patient infusion. Second, the
availability of IgE Abs with human constant regions (chimeric,
humanized, and fully human) targeting tumor antigens has
grown substantially (70, 72). Third, the high affinity binding
between IgE and FcεRI is very stable with a long half-life resulting
in an effective arming of MC, which would be able to target the
tumor and so doing induce tumor cell death. The presence of
dead tumor cells would facilitate their uptake and presentation
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FIGURE 6 | Mediators from FcεRI-challenged ADMC induce SK-BR-3 cell killing. (A) ADMC (1.3 × 106) were challenged with optimal concentrations of anti-FcεRI
stimuli (70% release) for 24 h and supernatants (XL media; no cells) from these ADMC were incubated with the MitoTrackerTM green-stained SK-BR-3 (105) in culture
medium containing optimal concentrations of PI and images taken before (left) and after (right) 96 h. (B) Quantification of overall PI fluorescence before and after
incubation. The increased number of red cells indicates breast cancer cell death as indicated by the PI (red) and quantified in showing overall PI fluorescence before
and after incubation. Graph represents average PI intensity from two separate experiments (±SD; *p = 0.0008). (C) Mediators from FcεRI-challenged ADMC induce
human breast cancer cell apoptosis. The same media from anti-FcεRI challenged ADMC were incubated with SK-BR-3 (105) for 72 h, cytospins prepared, fixed, and
incubated with Alexa Fluor 647 labeled, anti-human caspase 3 (left) or Alexa Fluor 647 labeled, isotype control Ab for caspase 3 (right). Representative panels are
shown. (D) Quantification of overall Alexa FluorTM 647 fluorescence before and after incubation with supernatants from FcεRI activated ADMC. *p = 0.01 SK-BR-3
apoptosis comparing anti-HER2/neu IgE-sensitized cells at day 0 vs. day 4 from three experiments. (E) Mediators from FcεRI-challenged ADMC induce SK-BR-3 cell
killing measured by caspase 3/7. ADMC (1.8 × 106) were challenged with optimal concentrations of anti-FcεRI stimuli (63% release) for 24 h and supernatants (no
cells) from these ADMC were incubated with SK-BR-3 (105) and caspase 3/7 green images taken before (left) and after (right) 96 h. The increased number of green
cells indicates breast cancer cell death as indicated by the caspase 3/7 and quantified by counting live vs. dead cells before and after incubation. (F) Graph represents
average percentage of cells from two separate experiments (±SD; *p = 0.002). (G) Blocking TNF-α significantly reduces SK-BR-3 cell death. SK-BR-3 were treated
and quantified as in (C) except anti-TNF-α Ab were added during the incubation time. *p = 0.028 Decrease in SK-BR-3 cell death when anti-TNF-α Ab are added to
the supernatants from anti-FcεRI stimulated ADMC.
of tumor antigens by antigen presenting cells (APC), eliciting
an adaptive broad-spectrum anti-tumor immunity. This would
increase due to MC local release of GM-CSF (19, 20) and
potentially the release of suppressors of regulatory T-cell (Tregs)
function as reported for IgE degranulation in murine MC (75).
Lastly, unlike other immune cells currently being used for cancer
immunotherapy (76), ADMC sensitized with anti-HER2/neu IgE
are equipped to kill tumor cells without genetic reprogramming,
which is time consuming and expensive (76).
In conclusion, it is shown that adipose tissue represents an
alternative source for human MC that are phenotypically and
functionally similar to primary MC. This new source of MC,
ADMC, can be used in research to address fundamental questions
in MC biology and to study IgE Abs including those targeting
tumor antigens. Importantly, ADMC exhibit tumoricidal activity
when armed with IgE Abs specific for a tumor antigen. Future
studies are needed to evaluate the utility of ADMC, sensitized
with tumor targeting IgE, to examine anti-tumor activity and
toxicity in in vivo cancer models to further validate this potential
new cancer immunotherapy strategy.
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